Neuropediatrics 2008; 39(5): 276-279
DOI: 10.1055/s-0029-1202833
Short Communication

© Georg Thieme Verlag KG Stuttgart · New York

Pyridoxine-dependent Epilepsy: Normal Outcome in a Patient with Late Diagnosis after Prolonged Status Epilepticus Causing Cortical Blindness

G. Kluger 1 , R. Blank 2 , K. Paul 3 , E. Paschke 3 , E. Jansen 4 , C. Jakobs 4 , H. Wörle 5 , B. Plecko 3
  • 1Klinik für Neuropädiatrie und Neurologische Rehabilitation, Epilepsiezentrum für Kinder und Jugendliche, BHZ Vogtareuth, Germany
  • 2Child Centre Maulbronn and University of Heidelberg, Maulbronn, Germany
  • 3Department of Pediatrics, Medical University Graz, Austria
  • 4Department of Clinical Chemistry, Vrije Universiteit Amsterdam, The Netherlands
  • 5Pädiatrie I, Olgahospital, Klinikum Stuttgart, Germany
Weitere Informationen

Publikationsverlauf

received 23.08.2008

accepted 21.01.2009

Publikationsdatum:
17. März 2009 (online)

Abstract

We report on a male proband with pyridoxine-dependent epilepsy (PDE) and neonatal seizure onset. At the age of 31 months, a prolonged status epilepticus led to severe neurological regression with cortical blindness, loss of speech and muscular hypotonia with slow recovery over the following 3 months. At 33 months of age pyridoxine therapy was initiated with excellent response and the boy remained seizure-free on pyridoxine monotherapy, except for two occasions with seizure recurrence 10 days after accidental pyridoxine withdrawal. alpha-aminoadipic semialdehyde dehydrogenase (antiquitin) deficiency was indicated by elevated pipecolic acid concentrations in plasma and alpha-aminoadipic semialdehyde excretion in urine. Molecular analysis of the antiquitin gene revealed a novel missense mutation c.57insA, while the mutation of the other allele remained unidentified so far. Despite the delay in diagnosis and prolonged status epilepticus, neuropsychological evaluations at the ages of 11 and 18 years demonstrated full-scale IQ of 93 and 92, respectively, with better verbal IQ (103 and 101) than performance IQ (85 and 82).

References

  • 1 Baxter P, Griffiths P, Kelly T. et al . Pyridoxine-dependent seizures: demographic, clinical, MRI and psychometric features, and effect of dose on intelligence quotient.  Dev Med Child Neurol. 1996;  38 998-1006
  • 2 Baxter P. Pyridoxine-dependent and pyridoxine-responsive seizures.  Dev Med Child Neurol. 2001;  43 416-420
  • 3 Baynes K, Tomaszewski Farias S, Gospe SM. Pyridoxine-dependent seizures and cognition in adulthood.  Dev Med Child Neurol. 2003;  45 782-785
  • 4 Goutieres F, Aicardi J. Atypical presentation of pyridoxine-dependent seizures: a treatable cause of intractable epilepsy in infants.  Ann Neurol. 1985;  17 117-120
  • 5 Heeley A, Pugh R, Clayton B. et al . Pyridoxol metabolism in vitamin B6-responsive convulsions of early infancy.  Arch Dis Child. 1978;  53 794-802
  • 6 Mikati MA, Trevathan E, Krishnamoorthy KS. Pyridoxine-dependent epilepsy: EEG investigation and long-term follow-up.  Electroenceph Clin Neurophys. 1991;  78 215-221
  • 7 Mills PB, Struys E, Jakobs C. et al . Mutations in antiquitinin individuals with pyridoxine-dependent seizures.  Nat Med. 2006;  12 307-309
  • 8 Ohtsuka Y, Hattori J, Ishida T. et al . Long-term follow-up of an individual with vitamin B6-dependent seizures.  Dev Med Child Neurol. 1999;  41 203-206
  • 9 Plecko B, Paul K, Paschke E. et al . Biochemical and molecular characterization of 18 patients with pyridoxine-dependent epilepsy and mutations of the antiquitin (ALDH7A1) gene.  Hum Mutat. 2007;  28 19-26
  • 10 Rankin PM, Harrison S, Chong WK. et al . Pyridoxine-dependent seizures: a family phenotype that leads to severe cognitive deficits, regardless of treatment regime.  Dev Med Child Neurol. 2007;  49 300-305

Correspondence

Dr. B. Plecko

Department of Pediatrics

Medical University Graz

Auenbruggerplatz 30

8036 Graz

Austria

eMail: barbara.plecko@meduni-graz.at